The purpose of this clinical study is to monitor NeoAdjuvant Chemotherapy through time domain Diffuse Optical Spectroscopy, correlate the optical results with conventional imaging techniques and pathological response and eventually predict the efficacy of NAC in breast cancer patients. Our seven wavelength (635 -1060 nm) optical mammograph is used to perform non-invasive measurements on patients undergoing NAC in this study. The broad spectral range helps us to fully analyze tissue composition, that includes hemoglobin, water lipids and collagen concentration, to track the tumor response during the course of the therapy. In this paper, we present the preliminary results of five patients.
|